WINNIPEG, MANITOBA -- (MARKET WIRE) -- November 06, 2006 -- Medicure Inc. (TSX: MPH)(AMEX: MCU), a cardiovascular focused biopharmaceutical company, today announced that an abstract outlining a recently completed meta-analysis comparing Single High-Dose Bolus AGGRASTAT® (tirofiban) and ReoPro® (abciximab) in patients undergoing percutaneous coronary intervention (PCI) will be presented at the 2006 Scientific Sessions of the American Heart Association (AHA), which is being held November 12-15, 2006 in Chicago, Illinois. Medicure acquired the exclusive U.S. rights to AGGRASTAT®, a glycoprotein (GP) IIb/IIIa inhibitor, in August 2006.
